Chronic pain

Lore & Background

Chronic pain is defined by duration—persisting or recurring for longer than 3 months—and is distinguished from acute pain by its lack of a clear, resolvable cause. The International Association for the Study of Pain (IASP) describes it as pain that continues beyond the usual recovery time from injury or illness. The ICD-11 classifies chronic pain under MG30, with subcategories such as primary chronic pain (MG30.0), which includes widespread pain (fibromyalgia), primary musculoskeletal pain, and complex regional pain syndrome. The DSM-5 defines chronic pain disorder (somatic symptom disorder with predominant pain) as typically lasting more than 6 months, but does not state 'without requiring physical or mental injury' as a defining criterion.

Reader's Guide

Chronic pain is a major public health issue, affecting 8% to 55.2% of populations across countries, with higher incidence in industrialized nations. In the US, 30-40% of people experience it, and annual costs are estimated at US$560-635 billion. It can lead to severe physical effects such as grey matter loss, insomnia, metabolic disorders, chronic stress, obesity, and heart attack, as well as mental health consequences like depression and neurocognitive disorders. Treatment includes drug therapy (opioids and non-opioids), cognitive behavioral therapy, and physical therapy, but there is no definitive cure. The pathophysiology involves neuroplastic changes, including wind-up phenomena and altered brain wave activity, and the etiology remains unclear, with theories pointing to proximal neural compression at the dorsal root ganglion. Chronic pain's impact on quality of life, productivity, and health is profound, and opioid use carries risks of dependence, overdose, and decreased life expectancy.

Did You Know?

• Chronic pain affects more people than diabetes, cancer, and heart disease.
• The ICD-11 classifies chronic pain under code MG30, with subcategories including primary, cancer-related, and neuropathic pain.
• Chronic pain can cause grey matter loss in the brain, insomnia, metabolic disorders, and heart attack.
• Opioid use for chronic pain is associated with decreased life expectancy and increased mortality.

The Symptomatic Landscape

CP/CPPS is defined by pelvic or perineal pain persisting beyond three months without any sign of urinary tract infection. The pain is not static—it fluctuates in intensity, swinging between mild discomfort and truly debilitating episodes. It can radiate toward the back and rectum, making even sitting a challenge. Men may feel it in the perineum, testicles, the tip of the penis, or the pubic and bladder regions. Beyond pain, the condition can bring dysuria, joint aches, muscle soreness, unexplained fatigue, abdominal discomfort, a constant burning sensation in the penis, and increased urinary frequency. Post-ejaculatory pain, driven by nerve and muscle activity, is considered a hallmark feature. When frequency and urgency dominate, clinicians may suspect interstitial cystitis instead, where inflammation centers on the bladder rather than the prostate. The condition affects roughly two to six percent of men, making it a common yet often underappreciated source of suffering.

Theories Behind the Pain

No single cause has been confirmed for CP/CPPS, but several competing theories have emerged. One prominent view frames the condition as a psychoneuromuscular disorder: anxiety or stress triggers unconscious, sustained contraction of pelvic floor muscles, generating trigger points and pain, which in turn fuels more anxiety in a self-reinforcing loop. A second line of thinking points to a complex interplay among psychological factors and dysfunction in immune, neurological, and endocrine systems. A 2016 review highlighted that while the peripheral nervous system may initiate the problem, the central nervous system appears to sustain the pain even after peripheral input ceases. Hormonal pathways are also under scrutiny; research into C21 11-oxygenated steroids suggests that enzyme deficiencies, particularly in CYP21A2, may drive abnormal androgen biosynthesis linked to the condition. Meanwhile, a 2003 study effectively ruled out bacterial infection as a meaningful cause, finding equal bacterial colonization in affected and unaffected men.

The Diagnostic Puzzle

Despite accounting for ninety to ninety-five percent of all prostatitis diagnoses, CP/CPPS remains a poorly understood disorder with no definitive diagnostic test. The US NIH classifies it into Category IIIa (inflammatory) and IIIb (non-inflammatory) based on the presence or absence of pus cells in expressed prostatic secretions. However, this distinction has proven of limited clinical utility. A 2006 study from Chinese researchers showed that both subgroups exhibited similarly elevated levels of the anti-inflammatory cytokine TGFβ1 and the pro-inflammatory cytokine IFN-γ, suggesting that if one looks beyond pus cells to more subtle inflammatory markers, the two categories blur together. A 2010 study further identified nerve growth factor as a potential biomarker. Routine serum PSA tests, prostate imaging, and screening for Chlamydia trachomatis or Ureaplasma have been found to offer no meaningful benefit to patients. Diagnosis ultimately rests on excluding other conditions such as bacterial prostatitis, benign prostatic hyperplasia, overactive bladder, and cancer.

A Broader Family of Conditions

In 2007, the NIDDK began grouping CP/CPPS alongside interstitial cystitis and painful bladder syndrome under the umbrella term Urologic Chronic Pelvic Pain Syndromes, or UCPPS. The MAPP Research Network has since reinforced that these conditions share closely related symptom profiles, including pain triggered by bladder filling. Therapies that have shown efficacy for interstitial cystitis, such as quercetin, have demonstrated some benefit in CP/CPPS as well. The network has expanded its investigative lens beyond traditional prostate- and bladder-focused research, exploring potential links between UCPPS and other chronic conditions frequently seen in the same patients, including irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome. Treatment recommendations reflect this complexity: multimodal therapy and physiotherapy are standard, while a trial of alpha-blocker medication or antibiotics may be considered in certain newly diagnosed cases. Some evidence also supports non-medication-based approaches, underscoring that no single intervention resolves the condition.